Posterior reversible encephalopathy syndrome during sunitinib therapy

Revue Neurologique

Volumn 164, Issue 6-7, 2008, Pages 605-607

  Cumurciuc, R ^a   Martinez Almoyna, L ^a   Henry, C ^a   Husson, H ^a   de Broucker, T ^a  

^a DELAFONTAINE HOSPITAL   (France)

Author keywords

Posterior reversible encephalopathy syndrome; Renal cell carcinoma; Sunitinib

Indexed keywords

CLONAZEPAM; FOSPHENYTOIN SODIUM; GADOLINIUM; SUNITINIB;

ABDOMINAL PAIN; ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BRAIN DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CONFUSION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMIPLEGIA; HOMONYMOUS HEMIANOPIA; HUMAN; KIDNEY CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY METASTASIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; TONIC CLONIC SEIZURE; VOMITING;

ADULT; ANGIOGENESIS INHIBITORS; BRAIN DAMAGE, CHRONIC; CARCINOMA, RENAL CELL; EPILEPSY, TONIC-CLONIC; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; PYRROLES; SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 45949111118     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.03.007     Document Type: Article

References (11)

1. Allen J.A., Adlakha A., and Bergethon P.R. Reversible posterior leucoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63 (2006) 1475-1478
2. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011-2019
3. Glusker P., Recht L., and Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354 (2006) 980-981
4. Govindarajan R., Adusumilli A., Baxter D.L., El-Khoueiry A., and Harik S.I. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24 (2006) e48
5. Hinchey J., Chaves C., Appignani B., Breen J., Pao L., Wang A., et al. A reversible posterior leucoencephalopathy syndrome. N Engl J Med 334 (1996) 494-500
6. Ishimori M.L., Pressman B.D., Wallace D.J., and Weisman M.H. Posterior Reversible Encephalopathy syndrome: another manifestation of CNS SLE. Lupus 16 (2007) 436-443
7. Lam C., Lim K.H., and Karumanchi A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46 (2005) 1077-1085
8. Martin G., Bellido L., and Cruz J.J. Reversible posterior leucoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25 (2007) 3559
9. Medioni J., Cojocarasu O., Banu E., Cassar-Queudeville A., Halimi P., and Oudard S. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol 2 (2007) 193-195
10. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
11. Ozcan C., Wong S.J., and Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354 (2006) 981-982